id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0898-0058,FDA,FDA-2011-N-0898,Reference 8 National Survey on the Effect of Oncology Drug Shortages on Cancer Care,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:17:20Z,,0,0,0900006481b7171f
FDA-2011-N-0898-0062,FDA,FDA-2011-N-0898,Reference 12 Drug Shortages Delay Cancer Clinical Trials,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:18:52Z,,0,0,0900006481b71723
FDA-2011-N-0898-0063,FDA,FDA-2011-N-0898,Reference 13 Executive Order 13588 - Reducing Prescription Drug Shortages,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-09T14:55:23Z,,0,0,0900006481b71724
FDA-2011-N-0898-0061,FDA,FDA-2011-N-0898,Reference 11 Buyer Beware: Drug Shortages and the Gray Market,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:18:25Z,,0,0,0900006481b71722
FDA-2011-N-0898-0055,FDA,FDA-2011-N-0898,"Reference 5 Clinical Science Symposium, Bridging Evidence to Clinical Care: Cost and Availability of Treatment",Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:16:35Z,,0,0,0900006481b7171c
FDA-2011-N-0898-0060,FDA,FDA-2011-N-0898,"Reference 10 Drug Shortages: National Survey Reveals High Level of Frustration, Low Level of Safety",Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:18:16Z,,0,0,0900006481b71721
FDA-2011-N-0898-0051,FDA,FDA-2011-N-0898,Reference 1 Executive Order 13588—Reducing Prescription Drug Shortages,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-09T14:31:46Z,,0,0,0900006481b71594
FDA-2011-N-0898-0049,FDA,FDA-2011-N-0898,Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products,Rule,Final Rule,2015-07-08T04:00:00Z,2015,7,2015-07-08T04:00:00Z,,2015-07-10T17:12:21Z,2015-16659,0,0,0900006481b71397
FDA-2011-N-0898-0071,FDA,FDA-2011-N-0898,Reference 21 - Are We Finally Winning the War on Cancer,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:22:29Z,,0,0,0900006481b7172c
FDA-2011-N-0898-0074,FDA,FDA-2011-N-0898,Reference 24 - Occupational Employment Statistics Query Survey,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:23:20Z,,0,0,0900006481b7172f
FDA-2011-N-0898-0067,FDA,FDA-2011-N-0898,Reference 17 Impact of Drug Shortages on U.S. Health Systems,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:20:20Z,,0,0,0900006481b71728
FDA-2011-N-0898-0077,FDA,FDA-2011-N-0898,Reference 27 - American FactFinder - Results,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:24:01Z,,0,0,0900006481b71732
FDA-2011-N-0898-0059,FDA,FDA-2011-N-0898,Reference 9 National Survey of the Impact of Drug Shortages in Acute Care Hospitals,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:17:30Z,,0,0,0900006481b71720
FDA-2011-N-0898-0070,FDA,FDA-2011-N-0898,Reference 20 - A Review of Industry Aides Found at Least 15 Deaths in the Last 15 Months from a Lack of Available Medicine,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-09T15:00:46Z,,0,0,0900006481b7172b
FDA-2011-N-0898-0073,FDA,FDA-2011-N-0898,Reference 23 - An Economic Evaluation of the War on Cancer,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:23:08Z,,0,0,0900006481b7172e
FDA-2011-N-0898-0052,FDA,FDA-2011-N-0898,Reference 2 Manual of Policies and Procedures,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-09T14:34:47Z,,0,0,0900006481b71595
FDA-2011-N-0898-0054,FDA,FDA-2011-N-0898,Reference 4 Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products; Final Rule,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:16:24Z,,0,0,0900006481b7171b
FDA-2011-N-0898-0068,FDA,FDA-2011-N-0898,"Reference 18 - Gray Market, Black Heart:  Pharmaceutical Gray Market Finds a Disturbing Niche During the Drug Shortage Crisis",Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:20:34Z,,0,0,0900006481b71729
FDA-2011-N-0898-0076,FDA,FDA-2011-N-0898,Reference 26 - U. S. Small Business Administration Table of Small Business Size Standards Matched to North American Industry Classification System Codes,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:23:49Z,,0,0,0900006481b71731
FDA-2011-N-0898-0053,FDA,FDA-2011-N-0898,Reference 3 SOPP 8506: Management of Shortages of CBER-Regulated Products,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:16:15Z,,0,0,0900006481b7171a
FDA-2011-N-0898-0069,FDA,FDA-2011-N-0898,Reference 19 - Navigating Drug Shortages in American Healthcare: A Premier healthcare alliance analysis,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:20:44Z,,0,0,0900006481b7172a
FDA-2011-N-0898-0072,FDA,FDA-2011-N-0898,Reference 22 - The Value of Health and Longevity,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:22:45Z,,0,0,0900006481b7172d
FDA-2011-N-0898-0050,FDA,FDA-2011-N-0898,List of References re Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-09T14:27:29Z,,0,0,0900006481b71593
FDA-2011-N-0898-0057,FDA,FDA-2011-N-0898,Reference 7 A Shortage of Everything Except Errors:  Harm Associated with Drug Shortages,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:17:10Z,,0,0,0900006481b7171e
FDA-2011-N-0898-0056,FDA,FDA-2011-N-0898,Reference 6 2012 ASA Drug Shortage Survey Results,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:16:46Z,,0,0,0900006481b7171d
FDA-2011-N-0898-0075,FDA,FDA-2011-N-0898,Reference 25 - The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-09T15:04:40Z,,0,0,0900006481b71730
FDA-2011-N-0898-0064,FDA,FDA-2011-N-0898,Reference 14 - Letter to Industry,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:19:19Z,,0,0,0900006481b71725
FDA-2011-N-0898-0066,FDA,FDA-2011-N-0898,Reference 16 A Review of FDA’s Approach to Medical Product Shortages,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:19:52Z,,0,0,0900006481b71727
FDA-2011-N-0898-0065,FDA,FDA-2011-N-0898,Reference 15 - Federal Register Volume 76 Issue 243,Supporting & Related Material,Background Material,2015-07-08T04:00:00Z,2015,7,,,2015-07-08T15:19:36Z,,0,0,0900006481b71726
FDA-2011-N-0898-0016,FDA,FDA-2011-N-0898,OMB Changes - Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products,Other,Memo,2013-11-18T05:00:00Z,2013,11,2013-11-18T05:00:00Z,,2013-11-18T16:50:37Z,,0,0,0900006481487651
FDA-2011-N-0898-0015,FDA,FDA-2011-N-0898,Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products,Proposed Rule,Request for Comment,2013-11-04T05:00:00Z,2013,11,2013-11-04T05:00:00Z,2014-01-04T04:59:59Z,2014-08-29T01:04:25Z,2013-25956,0,0,090000648146f1a4
FDA-2011-N-0898-0002,FDA,FDA-2011-N-0898,"OMB Changes - CDER2011187 Applications for Food and Drug Administration Approval to Market a New Drug: Revision of Postmarketing Reporting Requirements - Discontinuance; Interim final rule; request for comments, dated February 24, 2012",Other,Memo,2012-02-28T05:00:00Z,2012,2,2012-02-28T05:00:00Z,,2012-02-28T13:15:53Z,,0,0,0900006480fc48e2
FDA-2011-N-0898-0001,FDA,FDA-2011-N-0898,Applications for Food and Drug Administration Approval to Market New Drug: Revision of Postmarketing Reporting Requirements; Discontinuance,Rule,Notice of Interim Rule,2011-12-19T05:00:00Z,2011,12,2011-12-19T05:00:00Z,2012-02-18T04:59:59Z,2011-12-19T16:11:43Z,2011-32354,0,0,0900006480f85979